Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. - Wikidata - awgldk - TriplyDB

Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.

Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.

http://www.wikidata.org/entity/Q34774622

about

Nuclear receptors in bone physiology and diseases Heparan sulfate in skeletal development, growth, and pathology: the case of hereditary multiple exostoses Brief review of models of ectopic bone formation Validation of a Radiography-Based Quantification Designed to Longitudinally Monitor Soft Tissue Calcification in Skeletal Muscle From mysteries to medicines: drug development for fibrodysplasia ossificans progressive Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva.Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial.Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.International physician survey on management of FOP: a modified Delphi study.Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis.ACVR1 mutations in DIPG: lessons learned from FOP.ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant The skeleton in the closet Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis Progressive osseous heteroplasia: diagnosis, treatment, and prognosis Enhanced MSC chondrogenesis following delivery of TGF-β3 from alginate microspheres within hyaluronic acid hydrogels in vitro and in vivo.Retinoid receptors in bone and their role in bone remodeling.Management of high-grade gliomas in the pediatric patient: Past, present, and future.Molecular and cellular mechanisms of heterotopic ossification.BMP signaling mediated by constitutively active Activin type 1 receptor (ACVR1) results in ectopic bone formation localized to distal extremity joints.The immunological contribution to heterotopic ossification disorders.Pathogenesis and prevention strategies of heterotopic ossification in total hip arthroplasty: a narrative literature review and results of a survey in Germany.Apyrase as a novel therapeutic inhibitor of heterotopic ossification Current therapeutic strategies of heterotopic ossification--a survey amongst orthopaedic and trauma departments in Germany.Selective Retinoic Acid Receptor γ Agonists Promote Repair of Injured Skeletal Muscle in Mouse.Characterization of Heterotopic Ossification Using Radiographic Imaging: Evidence for a Paradigm Shift.Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.Tissue engineering and regenerative medicine: recent innovations and the transition to translation.Development of the endochondral skeleton Blast injuries and heterotopic ossification Anteroposterior and dorsoventral patterning are coordinated by an identical patterning clock.Rargb regulates organ laterality in a zebrafish model of right atrial isomerism.High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation.Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons Surgically‑induced mouse models in the study of bone regeneration: Current models and future directions (Review).

P2860

Q26853017-92BF97FD-8F54-4812-824E-09ED64606731 Q27005904-559F7829-236E-42EB-916A-29C89E157F48 Q27013942-8A705213-8570-4796-AD50-89B164962180 Q27333806-2B78CFED-B36B-46A4-A4D9-014059DD5D4D Q33555767-0365421D-33D4-470F-8E37-D30A8C58FC77 Q33587847-4E73C6D2-E31F-4BC9-817A-0D72192B87DC Q33589769-2DF74DD6-F657-41B9-A78A-41C01CAA366D Q33789889-A8DC4931-60FB-46D2-ADBA-797EB9D38318 Q33791574-88F34814-30AB-4DFD-B10B-D4FB68F77DCB Q34029378-8A7A5272-F754-4CCA-B64B-F1F6B3239398 Q34134675-D742124C-D88F-4887-BFA6-77BC141B20B2 Q34211818-6A4D8CFA-B8CE-4F9F-99EE-0F51C4F1D7F0 Q34354263-FB48F447-106F-464D-9D76-D59ABADEAC6F Q34552042-EBD2BD09-BB94-439C-BA90-58B0D71F4A6B Q34644842-F437737C-6DAD-4A28-94C6-90FF1B4FF1BB Q35063732-153A58A5-3DFC-4D90-A5AF-49F0FCFC9C9C Q35098667-D37F985C-3B8F-401F-ACDB-1F875E676109 Q35167063-35F71443-DF01-448F-B86A-3AB658B04D74 Q35206259-6754EEC5-E278-4EFC-91CD-38D9DB5B73F0 Q35212915-AB4BC2CA-F536-4465-85D9-D61FE58CB39B Q35424255-CFC170F9-0770-49FA-B1F3-F592D989F8D9 Q35563973-8C3D2F57-C002-49C9-A545-FA33321BEE4C Q35566376-3E85B2C5-3DC8-463C-AA0B-AAF010919CA1 Q35625198-01A60F02-8CEC-4040-B480-F24887F49088 Q35818208-2457DB3D-AB3D-4E69-92B1-773690DFC150 Q36134438-E1F192EF-26DF-4EF1-BC78-6FF104F6D045 Q36257772-A4500F41-7087-49FC-B7F9-6035AEB3D36E Q36394399-E40A936A-579F-41D9-A2DF-9C0346FECC40 Q36578816-6D7591F4-BA20-42BE-A89F-FCA8FA7701F0 Q36587765-183A850A-CD86-4853-8D8F-72A8184C2BD0 Q36629738-18B72D20-9E8D-4D71-895F-C8404E6D1BAF Q36765543-228CBB6F-9F80-4048-B46C-2A0B5E202E7F Q36783121-06DC7E2E-36E7-48B3-9E43-8347B7374E99 Q36969132-77A265C5-785C-4C52-BE6B-8AEC06A58BA0 Q37036154-0FB4B238-B4FC-409D-B2A5-9F5C3164B425 Q37469156-DD06912E-5B91-4934-B69A-70CE57F8E250 Q37566996-57EE5789-5B5F-4B6C-8174-46231EF23685 Q37686106-37B07014-A50D-43F5-A087-36B5C61458F3 Q37716166-B0514419-6089-4D66-9C3B-B05CBAD9ED6C Q37722128-73802075-6ED2-4A79-AFC0-BB860EBD529B

P2860

Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.

http://www.wikidata.org/entity/Q34774622

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@ast

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@en

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@nl

type

label

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@ast

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@en

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@nl

prefLabel

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@ast

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@en

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@nl

P1433

Q34774622-C2968859-92A4-4870-94E3-F5D829FC9AC4

P1476

Q34774622-F92B1B45-3B7C-4054-A365-3B12AF6CA50C

P2093

Q34774622-1E7B7122-3739-434D-8EAE-E28E42497295

Q34774622-4ACE6B95-08A7-47AE-800A-B222AED9FA5F

Q34774622-606BA397-3669-41D6-9755-CE86474203F6

Q34774622-72608229-7AAB-4ACC-994F-A31882630DE0

Q34774622-7A417ACC-BBB7-4099-8F88-494472F0D1F5

Q34774622-7DE02A83-23E0-4F98-A736-52F6F2615C0D

Q34774622-A2966BC5-7483-4CD1-BCDD-75696393DC4E

Q34774622-AAE7890E-5353-4845-B144-E41A22540731

Q34774622-AE76AF11-C6EF-4D92-BE89-8F447B361794

Q34774622-CA8F5B52-C802-4341-A4EC-18FD7B1EC3E5

P2860

Q34774622-0A29CA54-AE46-4842-96BA-280B5B6C5518

Q34774622-0CF2D43F-E5C3-42D6-A6D4-B1563A2A6601

Q34774622-14064146-1D92-40C5-8DD2-7E83836A617F

Q34774622-1912A7A9-5A0D-4A9C-8324-65E3C8A54FA9

Q34774622-1CD95B93-28E3-4843-B056-5D97DEF00881

Q34774622-21D32794-2125-4C85-907E-610871084F71

Q34774622-2C50FA48-7E15-4D60-AC32-85A2FA77B48E

Q34774622-320BF9E0-A239-4BE1-9C75-F7B52A7225B8

Q34774622-3D6434F9-9409-4969-B37F-7789F0B776A7

Q34774622-4071B82D-A22D-4FF8-AC1E-C05D7E89491C

P2888

Q34774622-90430CF0-C3CA-4ED4-9C66-3A397BF94EA9

P304

Q34774622-E93B3844-34CB-4AAF-AF78-C5F688A0A072

P31

Q34774622-05A62337-1F95-4CE9-9415-49BF6185AEAB

P356

Q34774622-A0C98D19-9CF8-459A-88D6-0B710737B92A

P407

Q34774622-44A5C951-A381-4DD0-A549-648BF327D44A

P433

Q34774622-51F13267-70E2-4EF4-99B2-D1498F5B9A59

P478

Q34774622-55B90B44-B186-4F2E-8D67-5BA0FF662900

P577

Q34774622-CD607986-AD30-4B9F-80B6-DDB0EC8C0F5F

P5875

Q34774622-C1AC52ED-3519-44EF-9D99-CF15F212A423

P6179

Q34774622-A2D203C0-4CEF-4FCD-AF13-25AF5AD97B37

P698

Q34774622-73445FF1-40FA-4404-AE8F-D42F8346898F

P932

Q34774622-31B6BC61-1945-4A4D-B3E8-4DD2482F3A12

P356

P1433

Nature Medicine

P1476

Potent inhibition of heterotop ...... noic acid receptor-γ agonists.

@en

P2093

Amber Hsu-Tsai Chi

http://www.w3.org/2001/XMLSchema#string

Christina Mundy

http://www.w3.org/2001/XMLSchema#string

Christine Macolino

http://www.w3.org/2001/XMLSchema#string

Johanna H Didizian

http://www.w3.org/2001/XMLSchema#string

Kengo Shimono

http://www.w3.org/2001/XMLSchema#string

Masahiro Iwamoto

http://www.w3.org/2001/XMLSchema#string

Maurizio Pacifici

http://www.w3.org/2001/XMLSchema#string

Motomi Enomoto-Iwamoto

http://www.w3.org/2001/XMLSchema#string

Roshantha A Chandraratna

http://www.w3.org/2001/XMLSchema#string

Wei-En Tung

http://www.w3.org/2001/XMLSchema#string

P2860

TGF-beta signal transduction

A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva

BMP type I receptor inhibition reduces heterotopic [corrected] ossification

ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development

Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma

Therapeutic applications for ligands of retinoid receptors

Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists

P2888

P304

454-460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2334

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50989726

http://www.w3.org/2001/XMLSchema#string

P6179

1013166953

http://www.w3.org/2001/XMLSchema#string

P698

21460849

http://www.w3.org/2001/XMLSchema#string

P932

3073031

http://www.w3.org/2001/XMLSchema#string